Too long to read? Go for the highlights below. Compass Pathways accelerates its planned commercial launch of COMP360 for treatment-resistant depression by up to a year after favourable engagement with the FDA. Phase 3 data remain the decisive hurdle, with key 9-week and 26-week readouts expected in early 2026. Despite rising losses linked to warrant liability adjustments, the company reports a strengthened cash position sufficient to operate into 2027. Regulatory momentum and

Too long to read? Go for the highlights below. MycoWorks is shutting its South Carolina biomanufacturing plant and transitioning from mycelium cultivation to processing third-party mycelium with its proprietary Rei-Tan™ tanning technology The company's latest Rei-Tan™ innovation increases mycelium tensile strength from approximately 4 MPa to 18 MPa addressing mechanical performance limitations that hindered leather substitution The strategic shift responds to capital scarcity

Too long to read? Go for the highlights below. Finnish biotechnology firm Kääpä Biotech has closed a €9 million strategic investment led by PeakBridge and Zintinus to expand production capacity and strengthen its position in the global nutraceutical market The funding will enable vertical integration expansion and scale operations to meet surging international demand from over 180 companies across 20+ markets This marks PeakBridge's second investment in Kääpä following a €90

Too long to read? Go for the highlights below. Copenhagen-based Matr Foods has raised €40M in total funding t(he largest amount secured by a Danish food tech startup) to build a commercial factory capable of producing 4,000 tonnes of mycelium protein annually by 2027. The company's clean-label products, made through solid-state fermentation of upcycled vegetables and legumes with fungi, have sold out every month in 2024 and 2025, bucking the downturn seen in plant-based meat

Article in partnership with Reshape Biotech , a Danish company that develops advanced lab automation robots and a cloud-based AI platform to accelerate biological research and development. Most readers here will know mycelium as a capable, adaptable builder of structures. In forest soils it colonises particulate matter, threads itself into gaps, and stabilises the whole. Visibuilt ’s work takes that familiar behaviour and applies it to a long‑standing industrial material: mi